Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 45

recruiting
3 968
countries
28
conditions
2 103

692 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Biliary tract disorder

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALKYLATING AGENTS

Neoplasm

Not recruiting

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Small cell lung cancer extensive stage

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Diffuse large B-cell lymphoma

Not recruiting

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.